Currentblue cross blue shield - south dakotaPolicy N/A

07.01.58 Radiofrequency Ablation and Alternative Ablative Methods for Chronic Facet Joint Mediated Neck, Back and Sacroiliac Joint Pain

This policy section reviews evidence on radiofrequency ablation (RFA) and alternative ablative methods (cooled RFA, pulsed RFA, cryoablation, chemical neurolysis, laser denervation, endoscopic RFA) for chronic facet joint pain (cervical, thoracic, lumbar) and sacroiliac joint (SIJ) pain, summarizing randomized and observational studies, guideline statements, and evidence quality to inform coverage decisions.

Policy Summary

Payerblue cross blue shield - south dakota

Policy07.01.58 Radiofrequency Ablation and Alternative Ablative Methods for Chronic Facet Joint Mediated Neck, Back and Sacroiliac Joint Pain

Policy CodePolicy N/A

Change TypeAnnual Review / Policy Renewed (January 2025)

Effective DateJuly 2022

Next Review DateJanuary 2025

Key ActionDocument diagnostic block pain relief percentage (e.g., ≥50% or ≥75%) and confirm contraindications before authorizing RFA; plan follow-up at 6–12 months and document outcomes.

SourceLink

POLICY UPDATE CHANGES

Policy history documents annual reviews and revisions through January 2025, with the most recent actions listed as Annual Review and Policy Renewed (January 2025).

insufficientEvidence strength for alternative ablative methods

lowQuality of evidence for CRFA (SIJ)

short-termObserved benefit duration in RCTs (SIJ RFA)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage summary

This section reviews evidence on radiofrequency ablation (RFA) and alternative ablative methods for chronic facet joint (cervical, thoracic, lumbar) and sacroiliac joint (SIJ) pain and takes a mixed coverage stance: conventional thermal RFA has some supportive evidence in selected lumbar facet joint patients, while RFA for SIJ pain and alternative ablative methods are considered insufficient/ investigational due to heterogeneous and limited-quality data. Interventions considered include conventional RFA (thermal), cooled RFA (CRFA), pulsed RFA (PRF), cryoablation (cryo/cryodenervation), chemical neurolysis (alcohol/phenol/glycerol), laser denervation, and endoscopic RFA. Overall conclusions note short-term benefits in some trials but important heterogeneity in techniques, small sample sizes, and limited long-term durability of effect.

Evidence-based conclusions / clinical summary

Coverage considerations informed by strength and quality of evidence:

ALL of the following

For sacroiliac joint (SIJ) pain, meta-analysis of available sham-controlled RCTs suggests a small short-term (1–3 months) effect of RFA, but randomized trials have methodological limitations and limited long-term durability; heterogeneity of RFA techniques limits generalizability.
Short-term benefit uncertain beyond 3 months; single RCT with 6–12 month follow-up showed no significant benefit versus exercise.
For cooled radiofrequency ablation (CRFA) for SIJ pain, evidence is low quality; CRFA may show promise for functional improvement but long-term effectiveness and QOL impact are uncertain.
Hayes 2024 assessment: low-quality evidence; Chou AHRQ 2021: moderate-large reduction at 1 month vs sham, moderate at 3 months; evidence beyond 6 months lacking.
For alternative ablative methods overall (laser denervation, chemical neurolysis, cryoablation, pulsed RFA, endoscopic RFA), current evidence is insufficient to establish safety and efficacy for chronic facet joint and SIJ pain.
Studies small, short follow-up, heterogeneous; further well-designed RCTs needed.
For lumbar facet joint pain, thermal RFA (conventional) has fair evidence supporting use with durable relief for at least six months when stringent diagnostic criteria applied (per NASS guidelines), but evidence for cryodenervation and other alternatives is insufficient.
NASS: Thermal RFA suggested (Grade B).

Systematic reviews and HTA assessments (AHRQ/Chou et al. 2021 and Hayes HTAs) identify modest, short-term pain and functional benefits for cooled RFA versus sham at 1–3 months but rate the overall evidence as low to moderate quality and limited beyond 6 months. Randomized trials are heterogeneous in technique and patient selection, with several small RCTs (e.g., Patel, Mehta) showing short-term benefit but single larger trials with longer follow-up failing to show durable advantage. Major assessments emphasize the need for larger, well-designed RCTs with consistent diagnostic selection and longer follow-up to resolve uncertainty.

Diagnostic blocks and patient selection

Diagnostic block / patient selection considerations

Guidance and commonly used diagnostic thresholds from societies and trials:

ANY of the following

Diagnostic SIJ or lateral branch blocks recommended prior to RFA to select candidates.
ASPN: diagnostic block for lateral sacral branches is highly recommended prior to RF; recommendation for ≥50% pain reduction prior to RF (though some societies use ≥75%).
Society threshold variations
- American Society of Interventional Pain Physicians: positive response to joint block considered at least 75% improvement in pain or ability to perform previously painful movements.>= 75% pain relief
- ASPN consensus: recommendation for 50% or greater reduction in pain prior to advancing to RF for lateral sacral branches.

Follow-up and repeat treatment guidance

Recommended follow-up and repeat treatment

Practice guidance on intervals and outcome assessment:

ALL of the following

Follow-up after alternative ablative methods may be required from 6 to 12 months to monitor for symptom recurrence and need for additional treatments.
Some studies provide up to 12–24 months follow-up but evidence is limited.
Best practice statement: RFA of the SIJ should be repeated no more than at six-month intervals when an improvement of 50% pain relief and functional improvement is seen.50% pain relief
ASPN best practice statement.

Coding

No procedural codes specified in this partmixed

No codes listed

Covered CPT / Report provider services using appropriate CPT/HCPCS/Revenue/ICD codesCPTCovered

64625
64633	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, single facet joint.
64635	Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, single facet joint.

Covered CPT - sacroiliac joint radiofrequencyCPTCovered

64625

Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (i.e., fluoroscopy or computed tomography).

Place/Type of Service guidancemixed

Place of Service	Outpatient/Inpatient
Type of Service	Surgery

Billing Rule

Use appropriate CPT/HCPCS/Revenue/ICD codes

Report services using appropriate procedure and diagnosis coding and follow place/type of service guidance.

CPT codes: 64625, 64633, 64635
Report services using appropriate CPT/HCPCS/Revenue/ICD codes and correct place/type of service

Background and evidence summary

This evidence review synthesizes randomized controlled trials, observational studies, systematic reviews, and HTA reports on RFA and alternative ablative techniques for chronic facet joint and SIJ pain. The literature is characterized by substantial heterogeneity in procedural technique (conventional, cooled, pulsed, palisade, strip lesion, endoscopic), diagnostic selection criteria, and outcome measures.

Many trials are small or single-center, often with short follow-up (most reporting 1–3 month outcomes), and several allowed crossover after short endpoints, limiting assessment of long-term durability. Overall, long-term data beyond 6–12 months are limited, and quality assessments (Hayes, AHRQ) rate evidence for CRFA and other alternatives as low to very low, with further high-quality RCTs needed.

Reference	Key finding
Patel et al (cooled RFA lateral branch RCT)	47% treatment success with cooled RFA vs 12% sham at 3 months; response durable to 12 months in completers
Van Tilburg et al (percutaneous RFA, sham-controlled)	No significant difference between RFA and sham at 3 months; both groups improved over time
Hayes Health Technology Assessment (2024)	CRFA evidence considered low quality; PRF very low quality; need for longer-term studies and uncertainty about long-term effectiveness and QOL impact
AHRQ comparative effectiveness review (Chou et al. 2021)	Cooled RFA: moderate-large pain and function benefit vs sham at 1 month and moderate at 3 months; evidence beyond 6 months lacking
Joo et al (2013) randomized alcohol vs RFA	Alcohol neurolysis median effective period 24 months vs RFA 10.7 months in small RCT of recurrent facet pain
Notable assessments (systematic reviews/meta-analyses: De Salvatore, Chappell, Chen et al.)	Meta-analyses indicate modest short-term (1–3 months) pain reduction with RFA/CRFA but heterogeneity, small trials, and limited long-term durability limit conclusions

Provider actions and requirements

Documentation Required

Document diagnostic block response

Document the quantitative percent pain relief from diagnostic SIJ or medial/lateral branch blocks in the chart and note whether the response meets accepted thresholds before performing RFA. Acceptable examples cited in guidance include at least 75% pain relief (ASIPP) or 50% or greater reduction (ASPN); record the exact percent reported by the patient.

Record quantitative percent pain relief from diagnostic blocks
Acceptable thresholds: >= 75% (ASIPP) or >= 50% (ASPN)

Prior Authorization

Candidate selection and contraindications

For prior authorization, confirm the patient does not have exclusionary conditions and that diagnostic block response thresholds are met and documented before approval.

Exclusion criteria: sacral fracture, tumor, radiculopathy, infection, coagulopathy
Requirement: documented diagnostic block response meeting accepted thresholds prior to authorization

Definitions

CRFA: Cooled radiofrequency ablation uses a water-cooled probe to create a larger lesion area than standard thermal RFA, aiming to denervate joint sensory nerves; evidence for SIJ and facet applications shows short-term improvements but is considered low quality and long-term benefit is uncertain.

PRF: Pulsed radiofrequency delivers short bursts of current that do not raise tissue temperature above ~42°C, intended to modulate nerve transmission without permanent thermal lesioning; evidence is limited and of very low quality for chronic facet and SIJ pain.

RFA: Conventional thermal radiofrequency ablation creates heat lesions (temperatures up to ~80°C) to denervate pain-transmitting nerves; for lumbar facet pain, there is fair evidence of durable relief for at least six months when stringent diagnostic criteria are applied, but for SIJ and many alternative approaches evidence is heterogeneous and insufficient.

Revision history

January 2025annual reviewLatest

Policy history documents annual reviews and revisions through January 2025, with the most recent actions listed as Annual Review and Policy Renewed.